Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1561 to 1575 of 2208 results for guidelines

  1. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

  2. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

  3. What overall osmolality (or concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

    the solution is compromised) that are commonly used as evidence in NICE guidelines, so the committee made the recommendation based on a...

  4. Diagnosis and management of type 1 diabetes in children, young people and adults (CG15)

    This guidance has been updated and replaced by NICE guidelines NG17, NG18 and NG19.

  5. What is the optimal ratio of non-nitrogen energy to nitrogen in parenteral nutrition for preterm and term babies?

    phosphate and amino acid recommendations (1.5.11, 1.5.2 and 1.5.3) in this guideline are appropriate. However, because the evidence was...

  6. WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

    In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.

  7. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued Reference number: GID-MT516

  8. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  9. InterDry for intertrigo (MIB192)

    NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .

  10. Patient and public involvement policy

    Read NICE's patient and public involvement policy.

  11. PneuX to prevent ventilator-associated pneumonia (HTG543)

    Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.

  12. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  13. Robot-assisted surgery for orthopaedic procedures: early value assessment (HTG743)

    Early value assessment (EVA) guidance on robot-assisted surgery for orthopaedic procedures.

  14. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

  15. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.